Shattuck Labs Inc
Company Profile
Business description
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Contact
500 W. 5th Street
Suite 1200
AustinTX78701
USAT: +1 512 900-4690
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
40
Stocks News & Analysis
stocks
Overvalued ASX share has overly ambitious profit target
stocks
7 undervalued US stocks that crushed earnings
stocks
Undervalued ASX share hitting on all cylinders
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,997.30 | 168.10 | -1.83% |
| CAC 40 | 8,271.68 | 80.32 | -0.96% |
| DAX 40 | 26,315.50 | 283.14 | -1.06% |
| Dow JONES (US) | 51,608.17 | 739.38 | -1.41% |
| FTSE 100 | 10,795.14 | 86.41 | -0.79% |
| HKSE | 23,508.17 | 245.67 | -1.03% |
| NASDAQ | 24,509.76 | 626.52 | -2.49% |
| Nikkei 225 | 58,860.43 | 801.59 | -1.34% |
| NZX 50 Index | 14,306.96 | 3.19 | 0.02% |
| S&P 500 | 7,416.59 | 145.08 | -1.92% |
| S&P/ASX 200 | 8,883.20 | 161.50 | -1.79% |
| SSE Composite Index | 3,584.58 | 17.99 | -0.50% |